Efficacy, safety and risk of augmentation of rotigotine for treating restless legs syndrome

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 40, Issue 1, 2013, Pages 326-333

  Inoue, Yuichi ^a   Hirata, Koichi ^b   Hayashida, Kenichi ^c   Hattori, Nobutaka ^d   Tomida, Takayuki ^e   Garcia Borreguero, Diego ^f  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c Sleep and Stress Clinic   (Japan)

^d JUNTENDO UNIVERSITY HOSPITAL   (Japan)

^e OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^f SLEEP RESEARCH INSTITUTE   (Spain)

Author keywords

Application site reactions; Augmentation; Quality of life; Responder rate; Restless legs syndrome; Rotigotine

Indexed keywords

PLACEBO; ROTIGOTINE;

ADULT; AGED; APPLICATION SITE REACTION; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FALLING; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; RISK ASSESSMENT; SIDE EFFECT; SLEEP QUALITY; SOMNOLENCE; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VOMITING;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DOPAMINE AGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX; TETRAHYDRONAPHTHALENES; THIOPHENES; TREATMENT OUTCOME;

EID: 84869829535     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.10.012     Document Type: Article

References (37)

1. Allen R.P., Earley C.J. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996, 19:205-213.
2. Allen R.P., Picchietti D., Hening W.A., Trenkwalder C., Walters A.S., Montplaisi J., et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the results the restless legs syndrome diagnosis and epidemiology workshop at the National Institute of Health. Sleep Med 2003, 4:101-119.
3. Allen R.P., Walters A.S., Montplaisir J., Hening W., Myers A., Bell T.J., et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005, 165:1286-1292.
4. Beneš H., García-Borreguero D., Ferini-Strambi L., Schollmayer E., Fichtner A., Kohnen R. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Sleep Med 2012, 13:589-597.
5. Berger K., Luedemann J., Trenkwalder C., John U., Kessler C. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 2004, 164:196-202.
6. Bjorvatn B., Leissner L., Ulfberg J., Gyring J., Karlsborg M., Regeur L., et al. Prevalence, severity and risk factors of restless legs syndrome in the general adult population in two Scandinavian countries. Sleep Med 2005, 6:307-312.
7. Buysse D.J., Reynolds C.F., Monk T.H., Berman S.R., Kupfer D.J. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989, 28:193-213.
8. Cawello W., Braun M., Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos 2009, 37:2055-2060.
9. Doi Y., Minowa M., Uchiyama M., Okawa M., Kim K., Shibui K., et al. Psychometric assessment of subjective sleep quality using the Japanese version of the Pittsburgh Sleep Quality Index (PSQI-J) in psychiatric disordered and control subjects. Psychiatry Res 2000, 97:165-172.
10. Ekbom K.A. Restless legs syndrome. Neurology 1960, 10:868-873.
11. Fukuhara S., Bito S., Green J., Hsiao A., Kurokawa K. Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan. J Clin Epidemiol 1998, 51:1037-1044.
12. García-Borreguero D., Allen R.P., Kohnen R., Högl B., Trenkwalder C., Oertel W., et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine International Restless Legs Syndrome Study Group Consensus Conference at the Max Planck Institute. Sleep Med 2007, 8:520-530.
13. García-Borreguero D., Kohnen R., Högl B., Ferini-Strambi L., Hadjigeorgiou G.M., Hornyak M., et al. Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med 2007, 8:455-463.
14. Hening W.A., Allen R.P. Restless legs syndrome (RLS): the continuing development of diagnostic standards and severity measures. Sleep Med 2003, 4:95-97.
15. Hening W.A., Allen R.P., Chaudhuri K.R., Hornyak M., Lee H.B., Winkelman J., et al. Clinical significance of RLS. Mov Disord 2007, 22(Suppl. 18):S395-S400.
16. Hening W.A., Allen R.P., Ondo W.G., Walters A.S., Winkelman J.W., Becker P., et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord 2010, 25:1675-1683.
17. Högl B., García-Borreguero D., Trenkwalder C., Ferini-Strambi L., Hening W., Poewe W., et al. Efficacy and augmentation during 6months of double-blind pramipexole for restless legs syndrome. Sleep Med 2011, 12:351-360.
18. Johns M.W. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991, 14:540-545.
19. Kawamura T., Sasagawa S., Masuda T., Honda S., Kinoshita M., Harada S., et al. Basic studies on the standardization of patch test. J Dermatol 1970, 80:301-314. (In Japanese).
20. Moller J.C., Korner Y., Cassel W., Meindorfner C., Kruger H.P., Oertel W.H., et al. Sudden onset of sleep and dopaminergic therapy in patients with restless legs syndrome. Sleep Med 2006, 7:333-339.
21. Nomura T., Inoue Y., Kusumi M., Oka Y., Nakashima K. Email-based epidemiological surveys on restless legs syndrome in Japan. Sleep Biol Rhythms 2008, 6:139-145.
22. Nomura T., Inoue Y., Kusumi M., Uemura Y., Nakashima K. Prevalence of restless legs syndrome in a rural community in Japan. Mov Disord 2008, 23:2363-2369.
23. Oertel W.H., Beneš H., García-Borreguero D., Geisler P., Högl B., Trenkwalder C., et al. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. Sleep Med 2008, 9:865-873.
24. Oertel W., Trenkwalder C., Beneš H., Ferini-Strambi L., Högl B., Poewe W., et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol 2011, 10:710-720.
25. Ondo W.G. Restless legs syndrome. Neurol Clin 2005, 23:1165-1185.
26. Ondo W.G., Jancovic J. Restless legs syndrome: clinicoetiologic correlates. Neurology 1996, 47:1435-1441.
27. Paulus W., Trenkwalder C. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol 2006, 5:878-886.
28. Reynolds N.A., Wellington K., Easthope S.E. Rotigotine: in Parkinson's disease. CNS Drugs 2005, 19:973-981.
29. Takegami M., Suzukamo Y., Wakita T., Noguchi H., Chin K., Kadotani H., et al. Development of a Japanese version of the Epworth Sleepiness Scale (JESS) based on item response theory. Sleep Med 2009, 10:556-565.
30. Tippmann-Peikert M., Park J.G., Boeve B.F., Shepard J.W., Silber M.H. Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 2007, 68:301-303.
31. Trenkwalder C., Hening W.A., Montagna P., Oertel W.H., Allen R.P., Walters A.S., et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008, 23:2267-2302.
32. Trenkwalder C., Beneš H., Poewe W., Oertel W.H., García-Borreguero D., de Weerd A.W., et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008, 7:595-604.
33. Trenkwalder C., Högl B., Benes H., Kohnen R. Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med 2008, 9:572-574.
34. Vetrugno R., Contin M., Baruzzi A., Provini F., Plazzi G., Montagna P. Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome. Mov Disord 2006, 21:254-258.
35. Walters A.S. Toward a better definition of the restless legs syndrome. Mov Disord 1995, 10:634-642.
36. Walters A.S., LeBrocq C., Dhar A., Hening W., Rosen R., Allen R.P., et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003, 4:121-132.
37. Winkelman J.W., Finn L., Young T. Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort. Sleep Med 2006, 7:545-552.